BioPharma
U.S. House Passes Right-to-Try Legislation on Second Attempt
The second time proved to be the charm for the U.S. House of Representatives to pass right-to-try legislation that would provide terminally ill patients access to experimental drugs without the approval of the U.S. FDA. Source: BioSpace
Read MoreGSK Is Now Favorite to Acquire Pfizer's Consumer Health Business
Now that Reckitt Benckiser has walked away from a deal, GlaxoSmithKline is now the favorite to acquire Pfizer’s consumer health business. Source: BioSpace
Read MoreArray BioPharma Touts Phase III Results for Melanoma Therapy
Array BioPharma Inc. released detailed results for its late-stage combination treatment for metastatic melanoma. Source: BioSpace
Read MoreArena Pharma Raising $352 Million Following Positive Phase II Data
Arena Pharmaceuticals is hoping to raise $352 million from a stock offering just days after releasing positive top-line results from its Phase II trial of etrasimod in ulcerative colitis. Source: BioSpace
Read MorePoor Mid-Stage Results Sink AbbVie’s Plans for Cancer Drug
After disappointing mid-stage results and discussions with the FDA, AbbVie will not ask for accelerated approval for its lung cancer drug. Source: BioSpace
Read MoreCelgene Partners with Prothena Therapeutics in Potential $2B Deal
Prothena Therapeutics has forged a collaboration with Celgene worth a potential $2B to develop new therapies for a broad range of neurodegenerative diseases. Source: BioSpace
Read MoreGlaxoSmithKline Is Taking a Tough Approach to Budgets
The head of GlaxoSmithKline’s pharmaceuticals division is pushing to cut its budget by 20 percent. Source: BioSpace
Read MoreSeattle Genetics Gains Another FDA Approval
Seattle Genetics announced today that the FDA has granted approval for its Adcetris drug to treat Hodgkins Lymphoma. Source: BioSpace
Read MoreIs There a Biotech Bubble Brewing in Boston?
Billions of dollars are being invested in Boston-based life science companies. Source: BioSpace
Read MoreTCR2 Therapeutics Snags $125 Million To Expand T-Cell Program
TCR2 Therapeutics has raised $125 million in Series B financing to advance two T-Cell receptor (TCR) programs through clinical proof-of-concept. Source: BioSpace
Read More